Globus Medical to acquire Nevro for $5.85 per share
Globus Medical (GMED) and Nevro Corp. (NVRO) have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies,
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,
Zacks.com on MSN5h
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition ...
Piper Sandler analyst Adam Maeder upgraded shares of Nevro Corp (NYSE:NVRO), a medical device company with a market ...
Hosted on MSN9h
Nevro upgraded to Neutral from Underweight at Piper SandlerPiper Sandler analyst Adam Maeder upgraded Nevro (NVRO) to Neutral from Underweight with a price target of $5.85, down from $6, after the company ...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSE: NVRO) to Globus Medical for $5.85 per share is fair to Nevro shareholders.
Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...
Nevro (NVRO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...
Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.
Canaccord raised the firm’s price target on Nevro (NVRO) to $5.85 from $4 and keeps a Hold rating on the shares. The firm noted Globus Medical ...
Stifel analysts maintained a Buy rating and a $92.00 price target for Globus Medical (NYSE:GMED) stock following the company's announcement of acquiring Nevro Corp . (NYSE:NVRO) for an equity value of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback